<DOC>
	<DOC>NCT01285843</DOC>
	<brief_summary>This is a monocentric, prospective, randomized clinical survey to verify if the periprosthetic remodelling brought about either the AMIStem or the Quadra femoral component is equivalent.</brief_summary>
	<brief_title>Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Hip Dislocation</mesh_term>
	<mesh_term>Hip Dislocation, Congenital</mesh_term>
	<criteria>Patients who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to the patient's surgery. Patients presenting with disease that meets the indications for use for Medacta implants defined by this study (onlabel use (enclosure 2)). Patients must be willing to comply with the pre and postoperative evaluation schedule. Patients with only one lower limb arthroplasty Patient with metabolic bone diseases, use of steroids or other drugs affecting bone metabolism Patients with osteoporosis (preop Tscore &lt; 2,5) Patients with significant comorbidities Patients with both hip and knee arthroplasty Patients with restricted mobility Patient with severe hip contracture Those with one or more medical conditions identified as a contraindication defined by the labeling on any Medacta implants used in this study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>